Copyright Reports & Markets. All rights reserved.

Global Influenzavirus B Infection Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Influenzavirus B Infection Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by Product
      • 1.4.2 APP-309
      • 1.4.3 CF-403
      • 1.4.4 GC-3106A
      • 1.4.5 KIN-1400
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by End User
      • 1.5.2 Clinic
      • 1.5.3 Hospital
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Influenzavirus B Infection Drug Market Size
      • 2.1.1 Global Influenzavirus B Infection Drug Revenue 2014-2025
      • 2.1.2 Global Influenzavirus B Infection Drug Sales 2014-2025
    • 2.2 Influenzavirus B Infection Drug Growth Rate by Regions
      • 2.2.1 Global Influenzavirus B Infection Drug Sales by Regions
      • 2.2.2 Global Influenzavirus B Infection Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Influenzavirus B Infection Drug Sales by Manufacturers
      • 3.1.1 Influenzavirus B Infection Drug Sales by Manufacturers
      • 3.1.2 Influenzavirus B Infection Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Influenzavirus B Infection Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Influenzavirus B Infection Drug Revenue by Manufacturers
      • 3.2.1 Influenzavirus B Infection Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Influenzavirus B Infection Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Influenzavirus B Infection Drug Price by Manufacturers
    • 3.4 Influenzavirus B Infection Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Influenzavirus B Infection Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Influenzavirus B Infection Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Influenzavirus B Infection Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Influenzavirus B Infection Drug Sales by Product
    • 4.2 Global Influenzavirus B Infection Drug Revenue by Product
    • 4.3 Influenzavirus B Infection Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Influenzavirus B Infection Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Influenzavirus B Infection Drug by Countries
      • 6.1.1 North America Influenzavirus B Infection Drug Sales by Countries
      • 6.1.2 North America Influenzavirus B Infection Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Influenzavirus B Infection Drug by Product
    • 6.3 North America Influenzavirus B Infection Drug by End User

    7 Europe

    • 7.1 Europe Influenzavirus B Infection Drug by Countries
      • 7.1.1 Europe Influenzavirus B Infection Drug Sales by Countries
      • 7.1.2 Europe Influenzavirus B Infection Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Influenzavirus B Infection Drug by Product
    • 7.3 Europe Influenzavirus B Infection Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Influenzavirus B Infection Drug by Countries
      • 8.1.1 Asia Pacific Influenzavirus B Infection Drug Sales by Countries
      • 8.1.2 Asia Pacific Influenzavirus B Infection Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Influenzavirus B Infection Drug by Product
    • 8.3 Asia Pacific Influenzavirus B Infection Drug by End User

    9 Central & South America

    • 9.1 Central & South America Influenzavirus B Infection Drug by Countries
      • 9.1.1 Central & South America Influenzavirus B Infection Drug Sales by Countries
      • 9.1.2 Central & South America Influenzavirus B Infection Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Influenzavirus B Infection Drug by Product
    • 9.3 Central & South America Influenzavirus B Infection Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Influenzavirus B Infection Drug by Countries
      • 10.1.1 Middle East and Africa Influenzavirus B Infection Drug Sales by Countries
      • 10.1.2 Middle East and Africa Influenzavirus B Infection Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Influenzavirus B Infection Drug by Product
    • 10.3 Middle East and Africa Influenzavirus B Infection Drug by End User

    11 Company Profiles

    • 11.1 AbbVie Inc
      • 11.1.1 AbbVie Inc Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 AbbVie Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 AbbVie Inc Influenzavirus B Infection Drug Products Offered
      • 11.1.5 AbbVie Inc Recent Development
    • 11.2 Adimmune Corp
      • 11.2.1 Adimmune Corp Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Adimmune Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Adimmune Corp Influenzavirus B Infection Drug Products Offered
      • 11.2.5 Adimmune Corp Recent Development
    • 11.3 Altravax Inc
      • 11.3.1 Altravax Inc Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Altravax Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Altravax Inc Influenzavirus B Infection Drug Products Offered
      • 11.3.5 Altravax Inc Recent Development
    • 11.4 Amarillo Biosciences Inc
      • 11.4.1 Amarillo Biosciences Inc Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Products Offered
      • 11.4.5 Amarillo Biosciences Inc Recent Development
    • 11.5 Aphios Corp
      • 11.5.1 Aphios Corp Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Aphios Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Aphios Corp Influenzavirus B Infection Drug Products Offered
      • 11.5.5 Aphios Corp Recent Development
    • 11.6 BioCryst Pharmaceuticals Inc
      • 11.6.1 BioCryst Pharmaceuticals Inc Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Products Offered
      • 11.6.5 BioCryst Pharmaceuticals Inc Recent Development
    • 11.7 Cadila Healthcare Ltd
      • 11.7.1 Cadila Healthcare Ltd Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Products Offered
      • 11.7.5 Cadila Healthcare Ltd Recent Development
    • 11.8 ContraFect Corp
      • 11.8.1 ContraFect Corp Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 ContraFect Corp Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 ContraFect Corp Influenzavirus B Infection Drug Products Offered
      • 11.8.5 ContraFect Corp Recent Development
    • 11.9 Daiichi Sankyo Company Ltd
      • 11.9.1 Daiichi Sankyo Company Ltd Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Products Offered
      • 11.9.5 Daiichi Sankyo Company Ltd Recent Development
    • 11.10 Fujifilm Holdings Corporation
      • 11.10.1 Fujifilm Holdings Corporation Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Products Offered
      • 11.10.5 Fujifilm Holdings Corporation Recent Development
    • 11.11 GlaxoSmithKline Plc
    • 11.12 Green Cross Corp
    • 11.13 Inovio Pharmaceuticals Inc
    • 11.14 Kineta Inc
    • 11.15 Medicago Inc
    • 11.16 MedImmune LLC
    • 11.17 Mucosis BV
    • 11.18 Novavax Inc
    • 11.19 Park Active Molecules
    • 11.20 Romark Laboratories LC

    12 Future Forecast

    • 12.1 Influenzavirus B Infection Drug Market Forecast by Regions
      • 12.1.1 Global Influenzavirus B Infection Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Influenzavirus B Infection Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Influenzavirus B Infection Drug Market Forecast by Product
      • 12.2.1 Global Influenzavirus B Infection Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Influenzavirus B Infection Drug Revenue Forecast by Product 2019-2025
    • 12.3 Influenzavirus B Infection Drug Market Forecast by End User
    • 12.4 North America Influenzavirus B Infection Drug Forecast
    • 12.5 Europe Influenzavirus B Infection Drug Forecast
    • 12.6 Asia Pacific Influenzavirus B Infection Drug Forecast
    • 12.7 Central & South America Influenzavirus B Infection Drug Forecast
    • 12.8 Middle East and Africa Influenzavirus B Infection Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Influenzavirus B Infection Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Influenzavirus B Infection Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Influenzavirus B Infection Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Influenzavirus B Infection Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Influenzavirus B Infection Drug in these regions.
      This research report categorizes the global Influenzavirus B Infection Drug market by top players/brands, region, type and end user. This report also studies the global Influenzavirus B Infection Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      AbbVie Inc
      Adimmune Corp
      Altravax Inc
      Amarillo Biosciences Inc
      Aphios Corp
      BioCryst Pharmaceuticals Inc
      Cadila Healthcare Ltd
      ContraFect Corp
      Daiichi Sankyo Company Ltd
      Fujifilm Holdings Corporation
      GlaxoSmithKline Plc
      Green Cross Corp
      Inovio Pharmaceuticals Inc
      Kineta Inc
      Medicago Inc
      MedImmune LLC
      Mucosis BV
      Novavax Inc
      Park Active Molecules
      Romark Laboratories LC

      Market size by Product
      APP-309
      CF-403
      GC-3106A
      KIN-1400
      Others
      Market size by End User
      Clinic
      Hospital
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Influenzavirus B Infection Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Influenzavirus B Infection Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Influenzavirus B Infection Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Influenzavirus B Infection Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Influenzavirus B Infection Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Influenzavirus B Infection Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now